top of page

Pioneer in Pharmaceutical Supply Chain Security Tech Seeking Investor in Becoming the Next Unicorn

Listing Code:

XYSW2B

State:

Not Disclosed

Category:

Pharmaceuticals & Supplements

Asking Price:

-

Revenue:

$1,057,912

XYSW2B
Company Overview

PRIME exits and American Healthcare Capital are proud exclusively represent a tech company focused on security and fraud prevention of drug supply chains. Founded in 2012, this company specializes in providing DEA-compliant storage and supply chain solutions that prioritize the safety and security of pharmaceuticals. The organization’s solution protects the pharmaceutical supply chain through innovative hardware, software, access control systems, and consulting services. The Company is a leader in pharmaceutical supply chain security, offering patented, DEA-compliant solutions for secure storage, access control, and drug diversion prevention.

The Company generates revenue through the sale of DEA-compliant safes, access control systems, subscription-based tracking solutions, and consulting services. Future revenue streams include AI-driven analytics and data services.

Traction and Financial Performance

The Company revenue has shown significant growth, increasing by 50% year-over-year, going from $708,256 in 2022 to $1,057,912 in 2023. Despite the revenue growth, the company reported a net loss of $5,078,067 in 2023, which was driven primarily by one-time, non-cash, stock-based compensation, as well as investments in financial accounting.

With revenue growth of 50% in the past year and significant market opportunities ahead, Scripps Safe is poised for expansion.

Market: Addressing a $16.5 billion U.S. market, the Company serves over 600 clients, including major healthcare providers and government agencies.

Problem: The pharmaceutical industry faces significant challenges related to drug diversion, where drugs are stolen from the lawful supply chain. This problem results in economic losses, with an estimated $72.65 billion lost annually due to drug diversion. Additionally, the healthcare industry experiences $120 billion in lost productivity and between $50-$150 billion in litigation and opioid settlements. Inefficiencies in the supply chain have also led to $25 billion in surplus inventory being wasted or expired.

Solution: The company provides a patented comprehensive system that ensures compliance with DEA, FDA, and state regulations, featuring advanced AI analytics, traceability, and secure storage.

Leadership: Led by a seasoned CEO and supported by a strong board of directors with deep industry experience, the company is equipped to navigate the complex landscape of pharmaceutical security.

Business Opportunity and Asking Price

The Company’s founder and management team, who have played integral roles in the development, planning, testing, patenting validating, developing effective sales pipelines inviting a strategic financial sponsor who can help them scale their business. To realize their global vision, the founder and other shareholders are open to all types of deal structures, including majority equity sale and roll-over equity. The asking price for this business opportunity is to be determined plus a potential earn out through discussions and negotiations.

Inquire About This Listing:

In order to learn more about our listing, you must:

1. Complete a Buyer Profile:

This profile will be used to pre-qualify buyers and determine whether we can share additional details about our listings. If you have already completed a Buyer Profile, disregard.

YOU ONLY NEED TO COMPLETE A BUYER PROFILE ONCE. 

2. Sign NDA with Listing Code:

To learn more about this listing, you must sign an NDA. When completing the NDA, you will need to copy the exact LISTING CODE and LISTING TITLE.

Listing Code:

XYSW2B

Listing Title:

Pioneer in Pharmaceutical Supply Chain Security Tech Seeking Investor in Becoming the Next Unicorn

Heading 4

Contact the Team

Jack Eskenazi American Healthcare Capital

Jack Eskenazi

President/Founder

American HealthCare Capital

Dr. Allen Nazeri DDS MBA.jpg

Dr. Allen Nazeri 

Managing Partner

PRIME exits

Join our mailing list to receive our latest news, and listings.

Thanks for submitting!

bottom of page